PlantForm Corp.
Betting a biosimilar antibody made in tobacco can challenge Herceptin
This article was originally published in Start Up
Executive Summary
PlantForm Corp. calls the antibodies it’s producing in tobacco plants “subsequent-entry-biologic” antibody drugs. The first marketed product it hopes to emulate is Roche’s Herceptin. PlantForm’s biosimilar version of Herceptin could come to market years before Roche’s IP is void, because a tobacco-based production method does not infringe on intellectual property covering antibodies made in mammalian cells.
You may also be interested in...
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.